Ulrich Schriek, Jean-Pascal Viola
Qiagen said that Ulrich Schriek will become senior advisor to Qiagen CEO Peer Schatz effective May 20, 2015. Schriek has spent 18 years leading Qiagen's business development activities, most recently as senior vice president and head of corporate business development and intellectual property and litigation.
Jean-Pascal Viola, current vice president and global head of mergers and acquisitions and corporate ventures at Qiagen, will take on Schriek's former role. Viola joined Qiagen in 2005 and has been instrumental in the acquisitions of Cellestis, Corbett, DxS, and Enzymatics, Qiagen said.
Drug firm ZS Pharma has appointed Genomic Health CEO Kimberly Popovits to its board of directors. Popovits, who is also president of Genomic Health and heads the company's board of directors, brings more than 30 years of life sciences industry experience. Before becoming CEO of Genomic Health in 2002, Popovits was senior VP of marketing and sales at Genentech, where she worked for 15 years, spearheading commercialization efforts.
Popovits serves on the boards of several other entities, including Northern California's life science association CLSA and the American Clinical Laboratory Association. She is also president of The Coalition for 21st Century Medicine, and the Women Health Care Executives named her Woman of the Year in 2008.
Fluidigm has hired Steve McPhail as general manager of the company's production genomics business. McPhail joins Fluidigm from Quintiles Transnational, where he served as president of the worldwide genomics business. He also previously served as president and CEO of Expression Analysis prior to its acquisition by Quintiles. McPhail has also held senior management positions at Argomed, Xanthon, TriPath Imaging, Dynex Technologies, and Abbott Laboratories.
Dame DeAnne Julius, Julie Brown
Dame DeAnne Julius has told Roche that she will not seek reelection at the company's 2016 annual meeting. Julius has been on Roche's board since 2002 and is chairperson of the audit committee.
The company said it plans to nominate Julie Brown as a new board member at the 2016 meeting. Brown is CFO at Smith & Nephew and was previously at AstraZeneca, where she held several positions including VP of group finance and interim CFO.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.